Zentalis Pharmaceuticals (ZNTL) Competitors $4.06 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.00 -0.06 (-1.38%) As of 05/22/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. JBIO, AVLN, COLL, XERS, and MRVIShould you buy Zentalis Pharmaceuticals stock or one of its competitors? MarketBeat compares Zentalis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zentalis Pharmaceuticals include Jade Biosciences (JBIO), Avalyn Pharma (AVLN), Collegium Pharmaceutical (COLL), Xeris Biopharma (XERS), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. ZNTL vs. JBIOZNTL vs. AVLNZNTL vs. COLLZNTL vs. XERSZNTL vs. MRVIHow does Zentalis Pharmaceuticals compare to Jade Biosciences?Jade Biosciences (NASDAQ:JBIO) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends. Is JBIO or ZNTL more profitable? Jade Biosciences' return on equity of -51.34% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Jade BiosciencesN/A -51.34% -47.32% Zentalis Pharmaceuticals N/A -53.61%-40.67% Does the media favor JBIO or ZNTL? In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 1 mentions for Jade Biosciences. Zentalis Pharmaceuticals' average media sentiment score of 0.49 beat Jade Biosciences' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, JBIO or ZNTL? Jade Biosciences has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Jade Biosciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJade BiosciencesN/AN/A-$127.41M-$2.02N/AZentalis Pharmaceuticals$67.43M4.29-$137.06M-$1.73N/A Which has more volatility & risk, JBIO or ZNTL? Jade Biosciences has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Do analysts prefer JBIO or ZNTL? Jade Biosciences currently has a consensus price target of $34.33, suggesting a potential upside of 54.59%. Zentalis Pharmaceuticals has a consensus price target of $5.83, suggesting a potential upside of 43.68%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Jade Biosciences is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jade Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 SummaryJade Biosciences and Zentalis Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.How does Zentalis Pharmaceuticals compare to Avalyn Pharma?Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk. Do analysts prefer ZNTL or AVLN? Zentalis Pharmaceuticals currently has a consensus target price of $5.83, indicating a potential upside of 43.68%. Avalyn Pharma has a consensus target price of $66.00, indicating a potential upside of 128.85%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14Avalyn Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ZNTL or AVLN more profitable? Avalyn Pharma's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -53.61% -40.67% Avalyn Pharma N/A N/A N/A Does the media favor ZNTL or AVLN? In the previous week, Avalyn Pharma had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 4 mentions for Avalyn Pharma and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.49 beat Avalyn Pharma's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, ZNTL or AVLN? Avalyn Pharma has lower revenue, but higher earnings than Zentalis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M4.29-$137.06M-$1.73N/AAvalyn PharmaN/AN/AN/AN/AN/A SummaryAvalyn Pharma beats Zentalis Pharmaceuticals on 5 of the 7 factors compared between the two stocks.How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?Collegium Pharmaceutical (NASDAQ:COLL) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment. Is COLL or ZNTL more profitable? Collegium Pharmaceutical has a net margin of 9.41% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical9.41% 95.18% 16.39% Zentalis Pharmaceuticals N/A -53.61%-40.67% Does the media prefer COLL or ZNTL? In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.65 beat Zentalis Pharmaceuticals' score of 0.49 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, COLL or ZNTL? Collegium Pharmaceutical has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$780.57M1.42$62.87M$2.0416.70Zentalis Pharmaceuticals$67.43M4.29-$137.06M-$1.73N/A Do analysts prefer COLL or ZNTL? Collegium Pharmaceutical currently has a consensus price target of $57.50, indicating a potential upside of 68.77%. Zentalis Pharmaceuticals has a consensus price target of $5.83, indicating a potential upside of 43.68%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Which has more volatility and risk, COLL or ZNTL? Collegium Pharmaceutical has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. SummaryCollegium Pharmaceutical beats Zentalis Pharmaceuticals on 10 of the 13 factors compared between the two stocks.How does Zentalis Pharmaceuticals compare to Xeris Biopharma?Xeris Biopharma (NASDAQ:XERS) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Which has more volatility & risk, XERS or ZNTL? Xeris Biopharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Do institutionals & insiders have more ownership in XERS or ZNTL? 42.8% of Xeris Biopharma shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by company insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, XERS or ZNTL? Xeris Biopharma has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$291.85M3.66$550K$0.06103.17Zentalis Pharmaceuticals$67.43M4.29-$137.06M-$1.73N/A Do analysts prefer XERS or ZNTL? Xeris Biopharma presently has a consensus target price of $10.80, suggesting a potential upside of 74.47%. Zentalis Pharmaceuticals has a consensus target price of $5.83, suggesting a potential upside of 43.68%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Xeris Biopharma is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Is XERS or ZNTL more profitable? Xeris Biopharma has a net margin of 3.81% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xeris Biopharma3.81% 735.00% 3.24% Zentalis Pharmaceuticals N/A -53.61%-40.67% Does the media favor XERS or ZNTL? In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.84 beat Zentalis Pharmaceuticals' score of 0.49 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryXeris Biopharma beats Zentalis Pharmaceuticals on 12 of the 15 factors compared between the two stocks.How does Zentalis Pharmaceuticals compare to Maravai LifeSciences?Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Which has more risk & volatility, ZNTL or MRVI? Zentalis Pharmaceuticals has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Which has higher earnings & valuation, ZNTL or MRVI? Maravai LifeSciences has higher revenue and earnings than Zentalis Pharmaceuticals. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M4.29-$137.06M-$1.73N/AMaravai LifeSciences$185.74M6.12-$130.77M-$0.71N/A Does the media refer more to ZNTL or MRVI? In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.64 beat Zentalis Pharmaceuticals' score of 0.49 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ZNTL or MRVI more profitable? Zentalis Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -53.61% -40.67% Maravai LifeSciences -51.07%-17.87%-9.08% Do analysts recommend ZNTL or MRVI? Zentalis Pharmaceuticals presently has a consensus price target of $5.83, suggesting a potential upside of 43.68%. Maravai LifeSciences has a consensus price target of $5.50, suggesting a potential upside of 25.00%. Given Zentalis Pharmaceuticals' higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14Maravai LifeSciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals have more ownership in ZNTL or MRVI? 50.3% of Maravai LifeSciences shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryMaravai LifeSciences beats Zentalis Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition ExportMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$289.02M$3.37B$6.43B$12.32BDividend YieldN/A2.26%2.76%5.28%P/E RatioN/A18.9121.0125.66Price / Sales4.29329.35615.84111.99Price / CashN/A125.1743.4956.67Price / Book1.587.0910.377.14Net Income-$137.06M$24.45M$3.57B$335.98M7 Day Performance11.85%5.45%6.01%3.56%1 Month Performance2.01%2.43%3.52%2.54%1 Year Performance238.33%62.98%34.13%35.05% Zentalis Pharmaceuticals Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals2.5806 of 5 stars$4.06flat$5.83+43.7%+238.3%$289.02M$67.43MN/A160Analyst ForecastJBIOJade Biosciences2.0982 of 5 stars$22.01-5.7%$34.33+56.0%N/A$1.15BN/AN/A20Gap UpAVLNAvalyn PharmaN/A$26.63-10.8%N/AN/A$1.11BN/AN/A51Analyst ForecastCOLLCollegium Pharmaceutical2.964 of 5 stars$33.65-0.4%$57.50+70.9%+18.1%$1.10B$780.57M16.50210XERSXeris Biopharma2.9898 of 5 stars$6.01-3.7%$10.80+79.7%+28.2%$1.08B$291.85M100.17290Positive News Related Companies and Tools Related Companies JBIO Competitors AVLN Competitors COLL Competitors XERS Competitors MRVI Competitors CVAC Competitors AKTS Competitors CRVS Competitors SVRA Competitors ALVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
